Organocatalytic Enantioselective Direct Additions of Aldehydes to 4-Vinylpyridines and Electron-Deficient Vinylarenes and Their Synthetic Applications

Q1 · CHEMISTRY

Article

Author: Li, Xiangmin ; Liu, Hongwei ; Xu, Li ; Wang, Wei ; Wang, Sinan ; Li, Hao ; Li, Jian ; Zhuang, Jinchen

We describe a synergistic catalysis strategy for the asymmetric direct addition of simple aldehydes to 4-vinylpyridines. By means of independent activation of weakly electrophilic 4-vinylpyridines by the Brønsted acid CF3SO3H (TfOH) and aldehydes by chiral diphenylprolinol tert-butyldimethylsilyl (TBDMS) ether-catalyzed formation of nucleophilic enamines in a cooperative manner, the previously unattainable highly enantioselective addition process has been realized for the first time. Notably, the power of the addition process is fueled by its high efficiency in the production of synthetically valued chiral pyridines. (1)H NMR studies of the process suggested that the nucleophilic enamine formed in situ from the chiral amine catalyst and the aldehyde is directly added to the trimeric 4-vinylpyridinium-derived species as a highly active electrophile generated from the 4-vinylpyridine in the presence of TfOH. Moreover, inspired by the similar electronic natures of pyridine and nitrobenzene, we have achieved an unprecedented chiral diphenylprolinol TBDMS ether-promoted, highly enantioselective direct addition of aldehydes to 2-nitrostyrenes without the use of TfOH as a cocatalyst. In this approach, introducing a strong electron-withdrawing group such as NO2, CF3, SO2Me, etc. on the 2-nitrostyrene creates a highly electrophilic vinyl moiety, which enables the direct addition of the in situ-formed enamine derived from the chiral amine promoter and the aldehyde. This method significantly expands the scope of the enantioselective addition process. While the electron-withdrawing nitro group is essential for activation of the vinyl group, we have demonstrated that it can be readily transformed to diverse functionalities. Furthermore, as shown, a chiral pyridine adduct serves as a key building block in the synthesis of the potent fibrinogen receptor antagonist L-734,217.

01 Mar 2001·The Journal of pharmacology and experimental therapeuticsQ3 · MEDICINE

Comparative specificity of platelet alpha(IIb)beta(3) integrin antagonists.

Q3 · MEDICINE

Article

Author: Lapalme, G ; Tardif, P ; Thibault, G

Several platelet alpha(IIb)beta(3) integrin antagonists have been designed as preventive agents against the formation of arterial thrombi. Although the potency of these compounds in inhibiting platelet aggregation is in the nanomolar range, their specificity on other integrins that can bind ligands through an arginine-glycine-aspartic acid (RGD) motif is far from being well established. For instance, some cyclic RGD peptides can also interact with alpha(v)beta(3) integrin. We used a novel pharmacological assay, based on SDS-stable interaction between (125)I-echistatin and RGD-dependent integrins, to evaluate the specificity of several RGD compounds on integrins present on rat cardiac fibroblasts and human skin fibroblasts. None of the RGD peptidomimetics tested (L-734,217, lamifiban, Ro 44-3888, SR 121566A, BIBU-52, XV459) could interact with either alpha(v)beta(3) and alpha(8)beta(1) on rat fibroblasts or with alpha(v)beta(3) and alpha(v)beta(1) on human fibroblasts. Cyclic RGD peptides showed some potency (3-80 microM) on rat and human integrins with an alpha(v) subunit. We also compared the potency of these compounds on platelets. All RGD compounds demonstrated IC(50) between 0.6 and 530 nM on basal human platelets. Activation of the receptor with thrombin resulted in a 2- to 60-fold increase in potency, with L-734,217 and BIBU-52 showing the largest difference. On basal and thrombin-activated rat platelets, only eptifibatide, DMP728, and XJ735 could displace (125)I-echistatin (IC(50) approximately 0.1-1.5 microM). These results indicate that RGD peptidomimetics have a specificity limited to alpha(IIb)beta(3) integrin, whereas cyclic RGD peptides can also interact with other RGD-dependent integrins, particularly those of the alpha(v) subunit family.

15 Jul 1999·BloodQ1 · MEDICINE

Fibrinogen Receptor Antagonist-Induced Thrombocytopenia in Chimpanzee and Rhesus Monkey Associated With Preexisting Drug-Dependent Antibodies to Platelet Glycoprotein IIb/IIIa

Q1 · MEDICINE

Article

Author: Bednar, Bohumil ; Gould, Robert J. ; Cook, Jacquelynn J. ; Holahan, Marie A. ; Bednar, Rodney A. ; Jumes, Patricia A. ; Hartman, George D. ; Cunningham, Michael E.

Most clinical trials with fibrinogen receptor antagonists (FRAs) have been associated with thrombocytopenia. This report describes the occurrence of thrombocytopenia in one chimpanzee and one rhesus monkey upon administration of potent FRAs. Chimpanzee A-264 experienced profound thrombocytopenia on two occasions immediately upon intravenous administration of two different potent FRAs, L-738,167 and L-739,758. However, an equally efficacious antiaggregatory dose of another potent antagonist, L-734,217, caused no change in platelet count. These compounds did not affect platelet count in five other chimpanzees or numerous other nonhuman primates. Flow cytometric analysis showed drug-dependent antibodies (DDAbs) in the plasma of chimpanzee A-264 that bound to platelets of chimpanzees, humans, and all other primates tested only in the presence of the compounds that induced thrombocytopenia. Rhesus monkey 94-R021 experienced thrombocytopenia upon administration of a different antagonist, L-767,679, and several prodrugs that are converted into the active form, L-767,679, in the blood. More than 20 other FRAs, including those that induced thrombocytopenia in chimpanzee A-264, had no effect on platelet count in this monkey. Flow cytometric measurements again identified DDAbs that reacted with platelets of all primates tested and required the presence of L-767,679. Screening for DDAbs in the plasma of 1,032 human subjects with L-738,167 and L-739,758 demonstrated that the incidence of these preexisting antibodies in this population was 0.8% ± 0.6% and 1.1% ± 0.6%, respectively.

100 Deals associated with L-734217

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Thrombosis	Phase 1	-	Merck Sharp & Dohme Corp.	-
Thrombosis	Phase 1	-	Merck Sharp & Dohme Corp.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

L-734217

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation